Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study

Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12 weeks...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 39(1993), 4 vom: 15. Apr., Seite 391-403
1. Verfasser: Aso, Y (VerfasserIn)
Weitere Verfasser: Akaza, H, Koiso, K, Kameyama, S, Koyanagi, T, Kawai, T, Kumamoto, Y, Tazaki, H, Funyu, T, Oshima, H
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1993
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial Clinical Trial, Phase II Controlled Clinical Trial English Abstract Journal Article Multicenter Study Testosterone 3XMK78S47O Flutamide 76W6J0943E mehr... Prolactin 9002-62-4 Luteinizing Hormone 9002-67-9 Follicle Stimulating Hormone 9002-68-0